Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu...

por de Haas, Sanne L., Slamon, Dennis J., Martin, Miguel, Press, Michael F., Lewis, Gail D., Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A.
Publicado 2023